The PD-L1 expression and CD8+ T cells infiltration were evaluated as two immune features in the study, because they are major participants within tumor microenvironment, and more importantly, they are predictors for better outcomes of anti-PD-1/PD-L1 therapy [21–25]. This evidence concerns the gene CD274 and neoplasm.